Trump announces trade deal with EU following months of negotiations
In a series of transactions reported to the SEC, Staffan Encrantz, a director and significant shareholder of Sight Sciences , Inc. (NASDAQ:SGHT), acquired a substantial amount of the company’s common stock. Between May 27 and May 29, Encrantz purchased a total of 128,189 shares, with transaction prices ranging from $3.29 to $3.71 per share. The total value of these purchases amounted to approximately $451,734. According to InvestingPro data, these purchases come as the stock shows strong momentum, with a 10% return over the past week and trading near its Fair Value.
These acquisitions increased Encrantz’s direct ownership to 1,157,705 shares. Additionally, Encrantz holds indirect ownership through trusts and investment funds, which collectively own over 5 million shares. The purchases were executed at varying price points, reflecting a weighted average price for each transaction date. InvestingPro analysis reveals the company maintains a strong balance sheet with more cash than debt, and its liquid assets exceed short-term obligations. Get deeper insights into SGHT and 1,400+ other stocks with InvestingPro’s comprehensive research reports.
In other recent news, Sight Sciences Inc. reported its first-quarter 2025 earnings, revealing a net loss per share of $0.28, which missed the expected $0.23. The company’s revenue for the quarter was $17.5 million, falling short of the projected $18.4 million. Despite these setbacks, Sight Sciences reaffirmed its full-year revenue guidance of $70 million to $75 million. The company is also navigating challenges from tariffs, which are expected to impact financials by up to $4.5 million, prompting a strategic shift in manufacturing operations out of China over the next nine to twelve months.
Needham maintained a Hold rating on Sight Sciences, expressing optimism about the company’s quarterly performance but opting not to upgrade the stock. The company’s TearCare system, designed for treating evaporative dry eye disease, has seen increased reimbursed volumes, indicating growing market acceptance. Sight Sciences also launched the next-generation OmniEdge technology, which is expected to help maintain its leadership in the minimally invasive glaucoma surgery market. The company continues to focus on addressing unmet medical needs in glaucoma and dry eye markets, anticipating reimbursement decisions for its TearCare product in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.